Search

Your search keyword '"Antibodies, Neoplasm adverse effects"' showing total 9 results

Search Constraints

Start Over You searched for: Descriptor "Antibodies, Neoplasm adverse effects" Remove constraint Descriptor: "Antibodies, Neoplasm adverse effects" Journal leukemia lymphoma Remove constraint Journal: leukemia lymphoma
9 results on '"Antibodies, Neoplasm adverse effects"'

Search Results

1. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.

2. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.

Catalog

Books, media, physical & digital resources

3. Charting the path to the cure of chronic lymphocytic leukemia: consolidation strategies currently lead the way.

4. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.

5. Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia.

6. Alemtuzumab in clinical practice: a British Columbia experience.

7. Alemtuzumab-induced syndrome of inappropriate anti-diuretic hormone.

8. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.

9. Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma.